Cargando…

α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation

BACKGROUND: Although evidence suggests that the prevalence of Parkinson’s disease (PD) is lower in smokers than in non-smokers, the mechanisms of nicotine-induced neuroprotection remain unclear. Stimulation of the α7 nicotinic acetylcholine receptor (α7-nAChR) seems to be a crucial mechanism underly...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuan, Hu, Jun, Wu, Jie, Zhu, Chenlei, Hui, Yujian, Han, Yaping, Huang, Zuhu, Ellsworth, Kevin, Fan, Weimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416733/
https://www.ncbi.nlm.nih.gov/pubmed/22624500
http://dx.doi.org/10.1186/1742-2094-9-98
_version_ 1782240433669144576
author Liu, Yuan
Hu, Jun
Wu, Jie
Zhu, Chenlei
Hui, Yujian
Han, Yaping
Huang, Zuhu
Ellsworth, Kevin
Fan, Weimin
author_facet Liu, Yuan
Hu, Jun
Wu, Jie
Zhu, Chenlei
Hui, Yujian
Han, Yaping
Huang, Zuhu
Ellsworth, Kevin
Fan, Weimin
author_sort Liu, Yuan
collection PubMed
description BACKGROUND: Although evidence suggests that the prevalence of Parkinson’s disease (PD) is lower in smokers than in non-smokers, the mechanisms of nicotine-induced neuroprotection remain unclear. Stimulation of the α7 nicotinic acetylcholine receptor (α7-nAChR) seems to be a crucial mechanism underlying the anti-inflammatory potential of cholinergic agonists in immune cells, including astrocytes, and inhibition of astrocyte activation has been proposed as a novel strategy for the treatment of neurodegenerative disorders such as PD. The objective of the present study was to determine whether nicotine-induced neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model occurs via α7-nAChR-mediated inhibition of astrocytes. METHODS: Both in vivo (MPTP) and in vitro (1-methyl-4-phenylpyridinium ion (MPP(+)) and lipopolysaccharide (LPS)) models of PD were used to investigate the role(s) of and possible mechanism(s) by which α7-nAChRs protect against dopaminergic neuron loss. Multiple experimental approaches, including behavioral tests, immunochemistry, and stereology experiments, astrocyte cell cultures, reverse transcriptase PCR, laser scanning confocal microscopy, tumor necrosis factor (TNF)-α assays, and western blotting, were used to elucidate the mechanisms of the α7-nAChR-mediated neuroprotection. RESULTS: Systemic administration of nicotine alleviated MPTP-induced behavioral symptoms, improved motor coordination, and protected against dopaminergic neuron loss and the activation of astrocytes and microglia in the substantia nigra. The protective effects of nicotine were abolished by administration of the α7-nAChR-selective antagonist methyllycaconitine (MLA). In primary cultured mouse astrocytes, pretreatment with nicotine suppressed MPP(+)-induced or LPS-induced astrocyte activation, as evidenced by both decreased production of TNF-α and inhibition of extracellular regulated kinase1/2 (Erk1/2) and p38 activation in astrocytes, and these effects were also reversed by MLA. CONCLUSION: Taken together, our results suggest that α7-nAChR-mediated inhibition of astrocyte activation is an important mechanism underlying the protective effects of nicotine.
format Online
Article
Text
id pubmed-3416733
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34167332012-08-11 α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation Liu, Yuan Hu, Jun Wu, Jie Zhu, Chenlei Hui, Yujian Han, Yaping Huang, Zuhu Ellsworth, Kevin Fan, Weimin J Neuroinflammation Research BACKGROUND: Although evidence suggests that the prevalence of Parkinson’s disease (PD) is lower in smokers than in non-smokers, the mechanisms of nicotine-induced neuroprotection remain unclear. Stimulation of the α7 nicotinic acetylcholine receptor (α7-nAChR) seems to be a crucial mechanism underlying the anti-inflammatory potential of cholinergic agonists in immune cells, including astrocytes, and inhibition of astrocyte activation has been proposed as a novel strategy for the treatment of neurodegenerative disorders such as PD. The objective of the present study was to determine whether nicotine-induced neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model occurs via α7-nAChR-mediated inhibition of astrocytes. METHODS: Both in vivo (MPTP) and in vitro (1-methyl-4-phenylpyridinium ion (MPP(+)) and lipopolysaccharide (LPS)) models of PD were used to investigate the role(s) of and possible mechanism(s) by which α7-nAChRs protect against dopaminergic neuron loss. Multiple experimental approaches, including behavioral tests, immunochemistry, and stereology experiments, astrocyte cell cultures, reverse transcriptase PCR, laser scanning confocal microscopy, tumor necrosis factor (TNF)-α assays, and western blotting, were used to elucidate the mechanisms of the α7-nAChR-mediated neuroprotection. RESULTS: Systemic administration of nicotine alleviated MPTP-induced behavioral symptoms, improved motor coordination, and protected against dopaminergic neuron loss and the activation of astrocytes and microglia in the substantia nigra. The protective effects of nicotine were abolished by administration of the α7-nAChR-selective antagonist methyllycaconitine (MLA). In primary cultured mouse astrocytes, pretreatment with nicotine suppressed MPP(+)-induced or LPS-induced astrocyte activation, as evidenced by both decreased production of TNF-α and inhibition of extracellular regulated kinase1/2 (Erk1/2) and p38 activation in astrocytes, and these effects were also reversed by MLA. CONCLUSION: Taken together, our results suggest that α7-nAChR-mediated inhibition of astrocyte activation is an important mechanism underlying the protective effects of nicotine. BioMed Central 2012-05-24 /pmc/articles/PMC3416733/ /pubmed/22624500 http://dx.doi.org/10.1186/1742-2094-9-98 Text en Copyright ©2012 Liu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Liu, Yuan
Hu, Jun
Wu, Jie
Zhu, Chenlei
Hui, Yujian
Han, Yaping
Huang, Zuhu
Ellsworth, Kevin
Fan, Weimin
α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation
title α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation
title_full α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation
title_fullStr α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation
title_full_unstemmed α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation
title_short α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation
title_sort α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an mptp mouse model via inhibition of astrocyte activation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3416733/
https://www.ncbi.nlm.nih.gov/pubmed/22624500
http://dx.doi.org/10.1186/1742-2094-9-98
work_keys_str_mv AT liuyuan a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation
AT hujun a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation
AT wujie a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation
AT zhuchenlei a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation
AT huiyujian a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation
AT hanyaping a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation
AT huangzuhu a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation
AT ellsworthkevin a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation
AT fanweimin a7nicotinicacetylcholinereceptormediatedneuroprotectionagainstdopaminergicneuronlossinanmptpmousemodelviainhibitionofastrocyteactivation